Primary completion date changed
Before: Aug 2026. After: Feb 2027.
Study sponsor: Candel Therapeutics, Inc. · CADL
Primary completion is the date data collection ends for the main study measures, not when results are published.
Before: Aug 2026. After: Feb 2027.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Biodistribution of aglatimagene besadenovec Measure: Biomarkers of immune activation and tumor burden Measure: Biomarkers of immune activation and tumor burden Measure: Biomarkers of immune activation and tumor burden. After: Measure: Biodistribution of aglatimagene besadenovec.
Before: 30 participants (planned). After: 45 participants (planned).
Before: Jun 2026. After: Aug 2026.